The endocannabinoid system: An emerging key player in inflammation

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 17, Issue 2, 2014, Pages 130-138

  Witkamp, Renger ^a   Meijerink, Jocelijn ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Cyclooxygenase 2; Diet; Endocannabinoidome; Metabolomics; N 3 fatty acids

Indexed keywords

EICOSANOIDS; ENDOCANNABINOIDS; HUMANS; INFLAMMATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, CANNABINOID;

EID: 84894027839     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000027     Document Type: Review

References (89)

1. Pertwee RG, Howlett AC, Abood M, et al. IUPHAR database (IUPHAR-DB). Cannabinoid receptors, introductory chapter. http://www.guidetopharmacolo gy.org/GRAC/FamilyIntroductionForward?familyId=13. [Accessed 2/1/2014].
2. Pertwee RG, Howlett AC, Abood ME, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010; 62:588-631.
3. Silvestri C, Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab 2013; 17:475-490.
4. Piscitelli F, Carta G, Bisogno T, et al. Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high fat-fed mice. Nutr Metab 2011; 8:51.
5. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346:561-564.
6. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365:61-65.
7. Tortoriello G, Rhodes BP, Takacs SM, et al. Targeted lipidomics in Drosophila melanogaster identifies novel 2-monoacylglycerols and N-acyl amides. PLoS One 2013; 8:e67865.
8. Hansen KB, Rosenkilde MM, Knop FK, et al. 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J Clin Endocrinol Metab 2011; 96:E1409-E1417.
9. Dang HT, Kang GJ, Yoo ES, et al. Evaluation of endogenous fatty acid amides and their synthetic analogues as potential anti-inflammatory leads. Bioorg Med Chem 2011; 19:1520-1527.
10. Farrell EK, Merkler DJ. Biosynthesis, degradation and pharmacological importance of the fatty acid amides. Drug Discov Today 2008; 13:558-568.
11. Alhouayek M, Muccioli GG. The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Molec Med 2012; 18:615-625.
12. Meijerink J, Balvers M, Witkamp R. N-acyl amines of docosahexaenoic acid and other n-3 polyunsatured fatty acids-from fishy endocannabinoids to potential leads. Br J Pharmacol 2013; 169:772-783.
13. Brown I, Cascio MG, Rotondo D, et al. Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators. Prog Lipid Res 2013; 52:80-109.
14. Silvestri C, Martella A, Poloso NJ, et al. Anandamide-derived prostamide F2a negatively regulates adipogenesis. J Biol Chem 2013; 288:23307-23321.
15. Woodward DF, Wang JW, Poloso NJ. Recent progress in prostaglandin F2a ethanolamide (prostamide F2a) research and therapeutics. Pharmacol Rev 2013; 65:1135-1147.
16. Maccarrone M, Gasperi V, Catani MV, et al. The endocannabinoid system and its relevance for nutrition. Annu Rev Nutr 2010; 30:423-440.
17. Naughton SS, Mathai ML, Hryciw DH, et al. Fatty acid modulation of the endocannabinoid system and the effect on food intake and metabolism. Int J Endocrinol 2013; 2013:361895.
18. Hansen HS, Artmann A. Endocannabinoids and nutrition. J Neurendocrinol 2008; 20:94-99.
19. Tsuboi K, Ikematsu N, Uyama T, et al. Biosynthetic pathways of bioactive N-acylethanolamines in brain. CNS Neurol Disord Drug Targets 2013; 12:7-16.
20. Wellner N, Diep TA, Janfelt C, et al. N-acylation of phosphatidylethanolamine and its biological functions in mammals. BBA-Mol Cell Biol L 2013; 1831:652-662.
21. Reisenberg M, Singh PK, Williams G, et al. The diacylglycerol lipases: structure, regulation and roles in and beyond endocannabinoid signalling. Philos Trans R Soc B Biol Sci 2012; 367:3264-3275.
22. Bisogno T. Endogenous cannabinoids: structure and metabolism. J Neuroendocrinol 2008; 20:1-9.
23. Ueda N, Tsuboi K, Uyama T. Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta 2010; 1801:1274-1285.
24. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007; 14:1347-1356.
25. Fonseca BM, Costa MA, Almada M, et al. Endogenous cannabinoids revisited: a biochemistry perspective. Prostaglandins Other Lipid Mediat 2013; 102-103:13-30.
26. Rouzer CA, Marnett LJ. Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev 2011; 111:5899-5921.
27. Yang R, Fredman G, Krishnamoorthy S, et al. Decoding functional metabolomics with docosahexaenoyl ethanolamide (DHEA) identifies novel bioactive signals. J Biol Chem 2011; 286:31532-31541.
28. Matias I, Gatta-Cherifi B, Tabarin A, et al. Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS One 2012; 7:e42399.
29. Hanlon EC, Stuhr K, Leproult R, et al. Circadian rhythm of circulating endocannabinoid, 2-arachidonoylglycerol concentrations following normal and restricted sleep. 23rd Annual Symposium on the Cannabinoids (ICRS) 2013; 6.
30. Joosten MM, Balvers MG, Verhoeckx KC, et al. Plasma anandamide and other N-acylethanolamines are correlated with their corresponding free fatty acid levels under both fasting and nonfasting conditions in women. Nutr Metab (Lond) 2010; 7:49.
31. Balvers MJ, Verhoeckx KM, Bijlsma S, et al. Fish oil and inflammatory status alter the n-3 to n-6 balance of the endocannabinoid and oxylipin metabolomes in mouse plasma and tissues. Metabolomics 2012; 8:1130-1147.
32. Hansen HS. Effect of diet on tissue levels of palmitoylethanolamide. CNS Neurol Disord Drug Targets 2013; 12:17-25.
33. Alawi K, Keeble J. The paradoxical role of the transient receptor potential vanilloid 1 receptor in inflammation. Pharmacol Ther 2010; 125:181-195.
34. Karaliota S, Siafaka-Kapadai A, Gontinou C, et al. Anandamide increases the differentiation of rat adipocytes and causes PPARg and CB1 receptor upregulation. Obesity 2009; 17:1830-1838.
35. Alhouayek M, Masquelier J, Muccioli GG. Controlling 2- arachidonoylglycerol metabolism as an anti-inflammatory strategy. Drug Discov Today 2013. (in press).
36. Balvers MGJ, Verhoeckx KCM, Meijerink J, et al. Time-dependent effect of in vivo inflammation on eicosanoid and endocannabinoid levels in plasma, liver, ileum and adipose tissue in C57BL/6 mice fed a fish-oil diet. Int Immunopharmacol 2012; 13:204-214.
37. Miller AM, Stella N. CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 2008; 153:299-308.
38. Lourbopoulos A, Grigoriadis N, Lagoudaki R, et al. Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res 2011; 1390:126-141.
39. Kerr DM, Harhen B, Okine BN, et al. The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. Br J Pharmacol 2013; 169:808-819.
40. Cao Z, Mulvihill MM, Mukhopadhyay P, et al. Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. Gastroenterology 2013; 144:808-817; e15.
41. Nomura DK, Morrison BE, Blankman JL, et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011; 334:809-813.
42. Hsu KL, Tsuboi K, Adibekian A, et al. DAGLb inhibition perturbs a lipid network involved in macrophage inflammatory responses. Nat Chem Biol 2012; 8:999-1007.
43. Okine BN, Norris LM, Woodhams S, et al. Lack of effect of chronic pretreatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. Br J Pharmacol 2012; 167:627-640.
44. Murphy N, Cowley TR, Blau CW, et al. The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation. J Neuroinflammation 2012; 9:79.
45. Di Marzo V,Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci 2008; 29:229-233.
46. Ozalp A, Barroso B. Simultaneous quantitative analysis of N-acylethanolamides in clinical samples. Anal Biochem 2009; 395:68-76.
47. Huggins JP, Smart TS, Langman S, et al. An efficient randomised, placebocontrolled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 2012; 153:1837-1846.
48. Li GL, Winter H, Arends R, et al. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Br J Clin Pharmacol 2012; 73:706-716.
49. Di Marzo V. Inhibitors of endocannabinoid breakdown for pain: not so FA(AH)cile, after all. Pain 2012; 153:1785-1786.
50. Di Marzo V, Skaper SD. Editorial: palmitoylethanolamide: biochemistry, pharmacology and therapeutic use of a pleiotropic anti-inflammatory lipid mediator. CNS Neurol Disord Drug Targets 2013; 12:4-6.
51. Skaper S, Facci L, Giusti P. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol Neurobiol 2013; 48:340-352.
52. Balvers MG, Verhoeckx KC, Meijerink J, et al. Measurement of palmitoylethanolamide and other N-acylethanolamines during physiological and pathological conditions. CNS Neurol Disord Drug Targets 2013; 12:23-33.
53. Keppel Hesselink JM, De Boer T, Witkamp RF. Palmitoylethanolamide: a natural body-own anti-inflammatory agent, effective and safe against influenza and common cold. Int J Inflammation 2013; 2013:151028.
54. Bettoni I, Comelli F, Colombo A, et al. Nonneuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. CNS Neurol Disord Drug Targets 2013; 12:34-44.
55. Esposito E, Cuzzocrea S. Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries. CNS Neurol Disord Drug Targets 2013; 12:55-61.
56. Melis M, Carta G, Pistis M, et al. Physiological role of peroxisome proliferatoractivated receptors type alpha on dopamine systems. CNS Neurol Disord Drug Targets 2013; 12:70-77.
57. Dalle Carbonare M, Del Giudice E, Stecca A, et al. A saturated N-acylethanolamine other than N-palmitoyl ethanolamine with anti-inflammatory properties: a neglected story. J Neuroendocrinol 2008; 20:26-34.
58. Meijerink J, Plastina P, Vincken J-P, et al. The ethanolamide metabolite of DHA, docosahexaenoylethanolamine, shows immunomodulating effects in mouse peritoneal and RAW264.7 macrophages: evidence for a new link between fish oil and inflammation. Br J Nutr 2011; 105:1798-1807.
59. Brown I, Cascio MG, Wahle KW, et al. Cannabinoid receptor-dependent and-independent antiproliferative effects of omega-3 ethanolamides in androgen receptor-positive and-negative prostate cancer cell lines. Carcinogenesis 2010; 31:1584-1591.
60. Brown I, Wahle KWJ, Cascio MG, et al. Omega-3 N-acylethanolamines are endogenously synthesised from omega-3 fatty acids in different human prostate and breast cancer cell lines. Prostaglandins Leukot Essent Fatty Acids 2011; 85:305-310.
61. Kim HY, Spector AA. Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function. Prostaglandins Leukot Essent Fatty Acids 2013; 88:121-125.
62. Maresz K, Pryce G, Ponomarev ED, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 2007; 13:492-497.
63. Caraceni P, Pertosa AM, Giannone F, et al. Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia. Gut 2009; 58:1135-1143.
64. Schafer A, Pfrang J, Neumuller J, et al. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br J Pharmacol 2008; 154:1047-1054.
65. Gaffal E, Cron M, Glodde N, et al. Cannabinoid 1 receptors in keratinocytes modulate proinflammatory chemokine secretion and attenuate contact allergic inflammation. J Immunol 2013; 190:4929-4936.
66. Guabiraba R, Russo RC, Coelho AM, et al. Blockade of cannabinoid receptors reduces inflammation, leukocyte accumulation and neovascularization in a model of sponge-induced inflammatory angiogenesis. Inflamm Res 2013; 62:811-821.
67. Pamplona FA, Ferreira J, Menezes de Lima O, et al. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc Natl Acad Sci 2012; 109:21134-21139.
68. Pertwee RG. Lipoxin A4 is an allosteric endocannabinoid that strengthens anandamide-induced CB1 receptor activation. Proceed Natl Acad Sci 2012; 109:20781-20782.
69. Basu S, Dittel B. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res 2011; 51: 26-38.
70. Basu S, Ray A, Dittel BN. Cannabinoid receptor 2 (CB2) plays a role in the generation of germinal center and memory B cells, but not in the production of antigen-specific IgG and IgM, in response to T-dependent antigens. PLoS One 2013; 8:e67587.
71. Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011; 50:193-211.
72. Tschöp J, Kasten KR, Nogueiras R, et al. The cannabinoid receptor 2 is critical for the host response to sepsis. J Immunol 2009; 183:499-505.
73. Csoka Bz, Németh ZnH, Mukhopadhyay P, et al. CB2 cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis. PLoS One 2009; 4:e6409.
74. Gui H, Sun Y, Luo ZM, et al. Cannabinoid receptor 2 protects against acute experimental sepsis in mice. Mediators Inflamm 2013; 2013:741303.
75. Anavi-Goffer S, Baillie G, Irving AJ, et al. Modulation of l-a-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem 2012; 287:91-104.
76. Di Marzo V, De Petrocellis L. Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc B Biol Sci 2012; 367:3216-3228.
77. Tsuji F, Murai M, Oki K, et al. Transient receptor potential vanilloid 1 agonists as candidates for anti-inflammatory and immunomodulatory agents. Eur J Pharmacol 2010; 627:332-339.
78. De Petrocellis L, Schiano Moriello A, Imperatore R, et al. A re-evaluation of 9-HODE activity at TRPV1 channels in comparison with anandamide: enantioselectivity and effects at other TRP channels and in sensory neurons. Br J Pharmacol 2012; 167:1643-1651.
79. Starowicz K, Makuch W, Korostynski M, et al. Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism. PLoS One 2013; 8:e60040.
80. Raman P, Kaplan BLF, Kaminski NE. 15-Deoxy-D12,14-prostaglandin J2-glycerol, a putative metabolite of 2-arachidonyl glycerol and a peroxisome proliferator-activated receptor g ligand, modulates nuclear factor of activated T cells. J Pharmacol Exp Ther 2012; 342:816-826.
81. Hu SSJ, Bradshaw HB, Chen JSC, et al. Prostaglandin E 2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkB activity. Br J Pharmacol 2008; 153:1538-1549.
82. Duggan KC, Hermanson DJ, Musee J, et al. (R)-Profens are substrateselective inhibitors of endocannabinoid oxygenation by COX-2. Nat Chem Biol 2011; 7:803-809.
83. Du H, Chen X, Zhang J, et al. Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-g. Br J Pharmacol 2011; 163:1533-1549.
84. Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152:1092-1101.
85. Schicho R, Storr M. A potential role for GPR55 in gastrointestinal functions. Curr Opin Pharmacol 2012; 12:653-658.
86. Balenga NAB, Aflaki E, Kargl J, et al. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res 2011; 21:1452-1469.
87. Henstridge CM, Balenga NA, Schrö der R, et al. GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 2010; 160:604-614.
88. Takenouchi R, Inoue K, Kambe Y, et al. N-arachidonoyl glycine induces macrophage apoptosis via GPR18. Biochem Biophys Res Commun 2012; 418:366-371.
89. Witkamp RF. Current and future drug targets in weight management. Pharm Res 2011; 28:1792-1818.